Authors : Shafqat Masrur Turza

Volume/Issue : Volume 10 - 2025, Issue 4 - April

Google Scholar : https://tinyurl.com/47v9f5fz

Scribd : https://tinyurl.com/4w4m3t2w

DOI : https://doi.org/10.38124/ijisrt/25apr1467

Google Scholar

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 15 to 20 days to display the article.

Abstract : The pharmaceutical manufacturer industry is a key player in health care at the global level. The industry is facing growing challenges in achieving sustainable waste management with the speedy rise of regulatory standards, material inefficiency, and environmental impact. The aim of this paper is to study the influence of internal initiatives like Lean Manufacturing, Industry 4.0 and Employee Engagement as well as external forces like Economic and Environmental Impacts and Regulatory Compliance, on sustainable waste reduction. The study used a quantitative survey method targeting pharmaceutical professionals and employed multiple regression analysis to measure those relationships. The results show that Lean Manufacturing and Industry 4.0 technologies significantly improve waste reduction and operational efficiency, while regulatory compliance is an important driver of sustainability. Employee engagement alone may not have as much impact as one might believe, but it does show impact when supported through structured training and digital initiatives. This study offers a framework for drug manufacturing which is strategic, integrative of technology, and regulatory-oriented to achievement lasting environment and economic sustainability.

Keywords : Lean Manufacturing; Industry 4.0; Sustainable Waste Reduction; Regulatory Compliance; Employee Engagement; Economic Impact; Environmental Sustainability.

References :

1. B. V. Chowdary and D. George, “Improvement of manufacturing operations at a pharmaceutical company: A lean manufacturing approach,” J. Manuf. Technol. Manag., vol. 23, no. 1, pp. 56–75, Dec. 2011, doi: 10.1108/17410381211196285.
2. I. C. Reinhardt, D. J. C. Oliveira, and D. D. T. Ring, “Current Perspectives on the Development of Industry 4.0 in the Pharmaceutical Sector,” J. Ind. Inf. Integr., vol. 18, p. 100131, Jun. 2020, doi: 10.1016/j.jii.2020.100131.
3. V. Veleva, G. Bodkin, and S. Todorova, “The need for better measurement and employee engagement to advance a circular economy: Lessons from Biogen’s ‘zero waste’ journey,” J. Clean. Prod., vol. 154, pp. 517–529, Jun. 2017, doi: 10.1016/j.jclepro.2017.03.177.
4. S. Shelke, V. Jadhav, A. Jain, and D. Shirsat, “Navigating Drug Regulatory Affairs: An Analytical Review of Compliance in the Pharmaceutical Industry,” vol. 01, no. 02.
5. E. Dotsenko, N. Ezdina, and S. Mudrova, “Zero Waste Technologies and Solution of Economic and Environmental Problems of Sustainable Development,” E3S Web Conf., vol. 105, p. 02008, 2019, doi: 10.1051/e3sconf/201910502008.
6. A. Jamwal, R. Agrawal, M. Sharma, G. S. Dangayach, and S. Gupta, “Lean manufacturing implementation challenges: a case study of pharmaceutical industries in Himachal Pradesh (India),” Int. J. Bus. Syst. Res., vol. 17, no. 4, pp. 462–481, 2023, doi: 10.1504/IJBSR.2023.131730.
7. A. Mastrantonas et al., “Identifying the effects of Industry 4.0 in the pharmaceutical sector: achieving the sustainable development goals,” Discov. Sustain., vol. 5, no. 1, p. 460, Dec. 2024, doi: 10.1007/s43621-024-00716-2.
8. K. Maaroufi, T. Tudor, M. Vaccari, A. Siala, and E. Mahmoudi, “An Evaluation of Staff Engagement with Infectious Healthcare Waste Management Policies: A Case Study of Tunisia,” Int. J. Environ. Res. Public. Health, vol. 17, no. 5, p. 1704, Mar. 2020, doi: 10.3390/ijerph17051704.
9. M. H. Ali, S. Zailani, M. Iranmanesh, and B. Foroughi, “Impacts of Environmental Factors on Waste, Energy, and Resource Management and Sustainable Performance,” Sustainability, vol. 11, no. 8, p. 2443, Apr. 2019, doi: 10.3390/su11082443.
10. N. Raja and L. K. Boopathi, “The Crucial Role of Regulatory Affairs: Navigating Compliance and Innovation in the Pharmaceutical Industry”.
11. B. Byrne, O. McDermott, and J. Noonan, “Applying Lean Six Sigma Methodology to a Pharmaceutical Manufacturing Facility: A Case Study,” Processes, vol. 9, no. 3, p. 550, Mar. 2021, doi: 10.3390/pr9030550.
12. “Teeceq.”
13. “Davis.”
14. W. M. Burdon and M. K. Sorour, “Institutional Theory and Evolution of ‘A Legitimate’ Compliance Culture: The Case of the UK Financial Service Sector,” J. Bus. Ethics, vol. 162, no. 1, pp. 47–80, Feb. 2020, doi: 10.1007/s10551-018-3981-4.
15. J. Harrison, R. E. Freeman, and M. Cavalcanti Sá De Abreu, “Stakeholder Theory As an Ethical Approach to Effective Management: applying the theory to multiple contexts,” Rev. Bus. Manag., pp. 858–869, Sep. 2015, doi: 10.7819/rbgn.v17i55.2647.
16. M. G. Tetteh-Caesar, S. Gupta, K. Salonitis, and S. Jagtap, “Implementing Lean 4.0: a review of case studies in pharmaceutical industry transformation,” Technol. Sustain., vol. 3, no. 3, pp. 354–372, Aug. 2024, doi: 10.1108/TECHS-02-2024-0012.
17. I. Joseph, “Importance of Compliance With Regulations in the Pharmaceutical Industry,” SSRN Electron. J., 2024, doi: 10.2139/ssrn.4679812.
18. M. Miozza, F. Brunetta, and F. P. Appio, “Digital transformation of the Pharmaceutical Industry: A future research agenda for management studies,” Technol. Forecast. Soc. Change, vol. 207, p. 123580, Oct. 2024, doi: 10.1016/j.techfore.2024.123580.
19. J. F. Hair, M. Sarstedt, C. M. Ringle, and J. A. Mena, “An assessment of the use of partial least squares structural equation modeling in marketing research,” J. Acad. Mark. Sci., vol. 40, no. 3, pp. 414–433, May 2012, doi: 10.1007/s11747-011-0261-6.
20. “Fornell.”
21. J. Henseler, C. M. Ringle, and M. Sarstedt, “A new criterion for assessing discriminant validity in variance-based structural equation modeling,” J. Acad. Mark. Sci., vol. 43, no. 1, pp. 115–135, Jan. 2015, doi: 10.1007/s11747-014-0403-8.